IDEAYA Biosciences (IDYA) has enrolled the first patient in its phase 1 clinical trial evaluating IDE892 in combination with IDE397 to treat non-small cell lung cancer and pancreatic cancer, the drugmaker said Monday.
The oncology company is also developing a third proprietary program for MTAP-deleted solid tumors via ongoing preclinical toxicology studies to back its filing of a new drug application with the US Food and Drug Administration in H1 of 2027, it said.
Shares of IDEAYA were up 1.4% pre-bell.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments